Recce Pharmaceuticals Ltd. · ASX:RCE
Recce Pharmaceuticals — Investor Presentation (January 2025)
35 slides from Recce Pharmaceuticals's investor presentation, January 2025

Slide 1: RCE Corporate Presentation
RCE Corporate Presentation ASX:RCE | FSE:R9Q January XXXX 2024 2025

Slide 2: Disclaimer
Disclaimer DISCLAIMER This pre sen tation has been pre pared by Recce Pharmaceuticals Ltd (the “Co mp any”). It do es not purpo rt to con tain all the info rmation tha t a prospective investo r may requir e in conne ction with any potential investment in the Company. Yo u shou ld n ot treat the cont

Slide 3: About Recce Pharmaceuticals Ltd
About Recce Pharmaceuticals Ltd Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a new class of Synthetic Anti-Infectives • Australian clinical-stage biotech company, with a United States presence • Qualified Infectious Disease Product designation – 10 years of market exclusivity plus fa

Slide 4: Board and Management Structure
Board and Management Structure Dr John Prendergast – Chairman Michele Dilizia – Executive Director & Chief Scientific BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU) Officer BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM US-based, current Chairman and Co-founder of Palatin Tech nologies,

Slide 5: Company Overview
Company Overview Recce Pharmaceuticals Ltd is a clinical-stage biotech company with a new class of novel synthetic anti-infectives Capital Structure – January 2025 RCE Share Price and Volume Chart – 12 Months (price shown in AUD) ASX & FSE Code RCE, R9Q 2,500,000 $0.80 Share Price AUD $0.4700 $0.70

Slide 6: The Need for a New Class of Antibiotics: Synthetic Anti-Infectives
The Need for a New Class of Antibiotics: Synthetic Anti-Infectives On-track to be the only global clinical stage company whose drug is shown to be efficacious against the full suite of ESKAPE pathogens. • NO pre-formed natural superbugs. • Very broad-spectrum coverage of bacteria with no signs of re

Slide 7: Strong Pipeline
Strong Pipeline Over Various Indications and Upcoming Inflection Points Expected 2026 Commercial Launch Phase III start H1 2025 • Appr ova l re ceived from the Indon esia n Drug an d Food Regula tion Au tho rity, B adan POM, to initiate its Reg istrational Phase 3 clinical trial in Indonesia • ABSS

Slide 8: Independent Study Undertaken on R327 MoA
Independent Study Undertaken on R327 MoA1 By Leading Experts in Bacterial MoA Analysis Stage 1 Stage 2 • Novel mechanism which targets rapid access to and shut down of bacterial energy production (ATP) which results in bacterial death of both active and resting bacteria. R327 arrests cell growth R32

Slide 9: RECCE Activity Against Escherichia coli
RECCE® 327 Activity Against Escherichia coli • E. coli grows fast. Eukaryotic cells healthy Without R327 R327 (3,000 ppm) and not affected. • R327 at 3,000 ppm shown to be highly effective against E. coli without affecting growing, healthy eukaryotic cells. • R327 rapidly and irreversibly shuts down

Slide 10: RECCE Activity Against Staphylococcus aureus
RECCE® 327 Activity Against Staphylococcus aureus • S. aureus bacterial growth slower than E. coli, not Without R327 R327 (2,300 ppm) affecting eukaryotic cells. • R327 at 2,300 ppm shows to be highly effective against S. aureus without affecting growing, healthy eukaryotic cells. • R327 rapidly and

Slide 11: RECCE Maintains Activity
RECCE® 327 Maintains Activity Number of repeats before displaying loss of antibiotic activity Bacteria* 2 4 6 8 10 12 14 16 18 20 22 24 25 Escherichia coli 25 repeats at time of discovery was sufficient for PCT patent applications, with no sign of resistance. Pseudomonas aeruginosa Staphylococcus au

Slide 12: Bactericidal Effect of RECCE on ESKAPE Pathogens
Bactericidal Effect of RECCE® 327 on ESKAPE Pathogens E. faecium ATCC S. aureus ATCC K. pneumoniae ATCC 19434 29213 43816 A. baumannii ATCC 17978 P. aeruginosa ATCC 27853 Enterobacter cloacae ATCC 13047 • Average time-kill curv es of R327 at various conc ent rat ions against strains of ESKAPE pathog

Slide 13: Strategic Opportunity in South-East Asia to Accelerate Clinical Program
Strategic Opportunity in South-East Asia to Accelerate Clinical Program Phase 3 Registrational Clinical Trial in Indonesia Topical Gel • Approval received from the Indonesian Drug and Food Regulatory Authority, Badan POM, to initiate Registrational Phase 3 clinical trial • Human Research Ethics Comm

Slide 14: Topical Clinical Programs Move into Phase III
Topical Clinical Programs Move into Phase III Phase I/II Clinical Trial – Treatment of Burn Wound Infections • Stage 1 Complete • Patients treated with R327 showed good indications of safety and tolerability • No serious adverse events reported among patients • Clinical investigators are preparing a

Slide 15: Phase I/II DFI Clinical Trial – Achieved Primary Endpoints
Phase I/II DFI Clinical Trial – Achieved Primary Endpoints • Patients recruited had mild skin and soft tissue DFI including multidrug-resistant Gram-positive and Gram-negative pathogens • Study met all primary end points • R327 well-tolerated in all patients; DFI’s resolved/cured *Patient was on sys

Slide 16: Phase II ABSSSI Clinical Trial – Dosing at Final Stages
Phase II ABSSSI Clinical Trial – Dosing at Final Stages Efficacy Data and Safety Approval Received NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES • Non-Data Safety Monitoring Board unanimously agree R327G is safe and well-tolerated in patients – demonstrating highly encoura

Slide 17: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 0 Day 1 Day 30 Day 0 – Recce treatment Day 0 – Recce treatment Day 1 – Recce treatment Day 30 – Recce treatment Pre-treatment infection First Recce gel applied Post treatment Post treatment • Patient A unresponsive to 4x daily Cepha

Slide 18: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 7 Day 10 Day 14 Day 0 – Recce treatment Day 7 – Recce treatment Day 10 – Recce treatment Day 14 – Recce treatment Significant bacterial infection Wound drying up Post treatment Wound improved, well tolerated • Pre-treatment of R327G

Slide 19: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 7 Day 14 Day 21 Day 0 – Pre-treatment wound swab Day 7 – Recce treatment Day 14 – Recce treatment Day 21 – Recce treatment • Pre-treatment wound swab on Day 0 showed a growing culture ✓ Day 21 post-treatment, the wound had of both G

Slide 20: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 3 Day 7 Significant bacterial infection Redness and swelling Day 0 – Pre-treatment Day 3 – Recce treatment Day 7 – Recce treatment • Pre-treatment of R327G showed significant bacterial infection, ✓ Day 7 post-treatment showed wound

Slide 21: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 3 Day 7 Day 0 – Pre-treatment Day 3 – Recce treatment Day 7 – Recce treatment • Pre-treatment (Day 0) X-rays showed infection deep within the ✓ Day 7 post R327G treatment showed wound underlying bone, tissue and around the nail, wit

Slide 22: Patient Case Study – TGA Special Access Scheme Category A
Patient Case Study – TGA Special Access Scheme Category A Day 0 Day 5 Significant bacterial infection Day 0 – Pre-treatment Day 5 – Recce treatment • Significant bacterial infection – septic ankle arthritis, peri- ✓ The discharge has cleared, and with no signs Left femoral prosthetic joint infection

Slide 23: R327 Faster Acting Than Existing Antibiotics
R327 Faster Acting Than Existing Antibiotics No Prolonged Exposure Needed • R327 kills pathogenic bacteria at a faster rate. • R327 designed to work faster than all existing antibiotics, reinforced by MoA work undertaken by experts in their field. “R327 kills bacteria in conditions where other antib

Slide 24: RECCE 327 Summary Results – Phase I – Complete
RECCE® 327 Summary Results – Phase I – Complete Double-blind, Placebo-controlled, Single Ascending-dose, Safety and Pharmacokinetic Study in Healthy Participants ✓ Safe and well tolerated at doses up to 6,000mg given as a 1-hour intravenous infusion; ✓ No Serious Adverse Events; – All AE’s mild or m

Slide 25: RECCE Concentrates Safely in the Urine
RECCE® 327 Concentrates Safely in the Urine Concentration of R327 Ratio Urine/Plasma in Urine Compared to Plasma 16x 17x 14x 9x In over 60 21x healthy subjects 16x – R327 primary route of elimination appears to be through – Opportunities for therapeutic in array of UTIs (uncomplicated the kidney to

Slide 26: RECCE Kills Quickly in the Urine
RECCE® 327 Kills Quickly in the Urine E. coli ATCC 25922 Treated with RECCE® 327 in Urine • R327 in the presence of human urine was able to 10.00 have a fast (near minutes) effect against E. coli 9.00 and irreversible Viable Bacteria (log CFU/ml) 8.00 • Bacteria could not be revived post-treatment •

Slide 27: Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial
Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial R327 has achieved multiple ‘fast infusion’ time stamps in line with intended future regulatory submissions Clinical Trial Complete • Assessing R327 at faster administration rates (<1 hour) 15 minutes • Trial aimed at positioning R327 as first pa

Slide 28: RECCE Activity Against Multiple Bacterial Infections
RECCE® 327 Activity Against Multiple Bacterial Infections Recce’s Anti-Infective Research (AIR) Unit – Located within Murdoch Children’s Research Institute, one of the top three children’s research institutes worldwide – Ongoing pre-clinical programs, exploring new research development opportunities

Slide 29: Sepsis – it's a big problem!
Sepsis – it’s a big problem! Sepsis is a life-threatening inflammatory response to infection that has spread in the body. Is the most expensive condition to 48.9 Cases of sepsis treat in the last 8 years5. Double the average cost per stay across all other million recorded worldwide1 conditions5. Kil

Slide 30: Sepsis Patient Journey
Sepsis Patient Journey Patient Presents at the Hospital Current Treatment Paradigm • Mortality from sepsis increases by as much as 8% for • Introducing broad-spectrum antibiotic (s) every hour that treatment is delayed. • Running antibiograms • Cost of sepsis care for inpatient admissions and skille

Slide 31: Robust Worldwide Intellectual Property Portfolio
Robust Worldwide Intellectual Property Portfolio Recce’s patent portfolio contains over 40 patents and patent applications in the world’s major markets. Patent Patent Patent Patent Expiry Expiry Expiry Expiry Filed Family 1 Family 2 Family 3 Family 4 Family 1 group relates to the Company’s Unique an

Slide 32: Manufacturing & Scalability
Manufacturing & Scalability Manufacturing facility in Sydney’s Macquarie Park • Raw materials plentiful and cheap – few $/Kg • No expensive waste – 99.9% product yield • Automated manufacture process – completing 5,000 doses a week under GMP • This in-house pilot facility provides clear benefits in

Slide 33: RECCE – Global Recognition
RECCE® 327 – Global Recognition R327 added to World Health Organization’s List of Antibacterial Products in Clinical Development • Global recognition by the World Health Organization (WHO) – inclusion underscores significance of R327 in combating antimicrobial resistance. • Unique Mechanism of Actio

Slide 34: Summary – Significant Opportunities Ahead
Summary – Significant Opportunities Ahead Proprietary first-in-class, broad-spectrum anti-infectives against bacteria, protected by Composition of Matter Patent. Fast development plans targeting: Sepsis, UTI/Urosepsis, Burn Wounds and Acute Bacterial Skin and Skin Structure Infections (ABSSSI), incl

Slide 35: Thank you
Thank you @0@ = recce.com.au
Source: Internet Archive copy of recce.com.au
More decks from Recce Pharmaceuticals Ltd.
Shareholder Meeting (November 2026)19 slides · Nov 6, 2026
Investor Presentation (November 2026)45 slides · November 2026
Investor Presentation (October 2026)42 slides · October 2026
Shareholder Meeting (September 2026)10 slides · Sep 2, 2026
Investor Presentation (September 2026)42 slides · September 2026
Investor Presentation (August 2026)40 slides · August 2026